Targacept receives $304,000 grant from Michael J. Fox Foundation
Michael J. Fox
Related Blog Posts
- AstraZeneca makes $200 million drug development payment to Targacept
- Targacept lands potential $1.2 billion deal with AstraZeneca
- Targacept set for inclusion in NASDAQ biotech index
- Targacept turns in profitable quarter, but year remains at a loss
- Trial results spark stampede for Targacept stock
- Its stock soaring in value, Targacept looks to raise $46 million
- In his own words: Targacept CEO touts treatment for depression
- Michael J. Fox Foundation awards Targacept $600,000 grant
On The Web
- Michael J. Fox Foundation
- Targacept
- Local Tech Wire at Twitter - sign up today for latest news alerts
Site Search
Get the latest news alerts: Follow LTW at Twitter.
Local Tech Wire
WINSTON-SALEM, N.C. – For the second time in six months, the Michael J. Fox Foundation for Parkinson’s Research is funding research by Targacept (Nasdaq: TRGT).
The foundation is providing a grant worth $304,000 to Targacept for a program involving a Parkinson’s Disease biomarker.
If Targacept can identify one or more biomarkers in people with Parkinson’s, the disease could be diagnosed earlier and also identify people for clinical trials. Biomarkers also help track the impact of a drug and whether it is achieving the desired effect.
The research, which will last one year, will be led by Daniel Yohannes, Targacept’s director of drug discovery.
“Biomarker research could prove to be very valuable in the development of novel therapeutics for Parkinson’s disease,” said Targacept Chief Executive Officer J. Donald deBethizy.
Fox, a longtime popular actor, is fighting Parkinson’s.
Kristen Jordan, who is director of behavioral pharmacology at Targacept, is the principal investigator on the $600,000 grant that the Fox Foundation awarded the company last July.
Targacept is focused on research into neuronal nicotinic receptors, or NNRs. They are a class of proteins in the nervous system that control levels of chemical messengers such as dopamine. According to Targacept, nicotine has been linked to over-stimulation of dopamine in brain regions that are involved in feelings of reward and pleasure.,
Featured
E-mail Preferences
The Skinny
- Who won 'Social Bowl'? Super Bowl ads paying fans to play
- RTP broadband firm Overture, minus two top execs, launches new look
- Will RTP-based ChannelAdvisor go public? They're thinking
- What brands are winning Super Bowl hype? Two Durham firms to find out
- In Super Bowl of social media, Patriots win, Triangle firm says
- Big job cuts coming at IBM? Don't be surprised
- Erskine Bowles is among those who can cash in big time on Facebook IPO
- Ignore Facebook hype - Check out 'risk factors,' too
- Facebook vs. Google IPO: Which deal ranks better?
- Triangle StartUp Factory says business already booming